Immune Regulation News Volume 8.25 | Jul 15 2016

TOP STORY

Strategies to Mimic Fasting during Chemotherapy Enhance Anticancer T Cell Activity in Mice

Two independent studies in mice showed that fasting, either through diet or drugs, during chemotherapy helps increase the presence of cancer-killing T cells. The research teams showed that rodents that received caloric restriction mimetics alone or chemotherapy combined with a fasting-mimicking diet had smaller tumor masses over time than those that received only chemotherapy. [Press release from Cell Press (EurekAlert!) discussing online prepublications in Cancer Cell] Press Release | Abstract 1 | Abstract 2

(Ranked by impact factor of the journal)

Continuous Effector CD8⁺ T Cell Production in a Controlled Persistent Infection Is Sustained by a Proliferative Intermediate Population

Researchers examined the cellular mechanisms that maintain ongoing T effector responses using a mouse model for persistent Toxoplasma gondii infection. In mice expressing the protective MHC-I molecule, H-2L^d, a dominant T effector response against a single parasite antigen was maintained without a contraction phase, correlating with ongoing presentation of the dominant antigen. [Immunity] Abstract | Graphical Abstract

WNK1 Kinase Balances T Cell Adhesion versus Migration In Vivo

Scientists found that WNK1 is a negative regulator of integrin-mediated adhesion, whereas it acts as a positive regulator of migration via the kinases OXSR1 and STK39 and the ion co-transporter SLC12A2. [Nat Immunol] Abstract

Nonoverlapping Roles of PD-1 and FoxP3 in Maintaining Immune Tolerance in a Novel Autoimmune Pancreatitis Mouse Model

The authors found that mice with partial FoxP3 insufficiency developed early-onset lympho-proliferation and lethal autoimmune pancreatitis only when programmed-death 1 (PD-1) is absent. [Proc Natl Acad Sci USA] Abstract

Meningeal Mast Cell-T Cell Crosstalk Regulates T Cell Encephalitogenicity

Investigators identified mast cells in the meninges, tripartite tissues surrounding the brain and spinal cord, as important contributors to antigen-specific T helper cell accumulation and GM-CSF expression. [J Autoimmun] Abstract

Protein SUMOylation Is Required for Regulatory T Cell Expansion and Function

The authors report that selective deletion of Ubc9 within the regulatory T lineage results in fatal early-onset autoimmunity similar to Foxp3 mutant mice. [Cell Rep] Full Article | Graphical Abstract

Exploring the Induction of Preproinsulin-Specific Foxp3⁺ CD4⁺ Treg Cells that Inhibit CD8⁺ T Cell-Mediated Autoimmune Diabetes by DNA Vaccination

Investigators showed that the injection of preproinsulin (ppins)-expressing pCI/ppins vector into PD-1- or PD-L1-deficient mice induced K^b/A12-21-monospecific CD8⁺ T cells and autoimmune diabetes. [Sci Rep] Full Article

Interferon Regulatory Factor 3 Is a Key Regulation Factor for Inducing the Expression of SAMHD1 in Antiviral Innate Immunity

Scientists report that inducing SAMHD1 upregulation is part of an early intrinsic immune response via TLR3 and RIG-I/MDA5 agonists that ultimately induce the nuclear translocation of the interferon regulation factor 3 protein. [Sci Rep] Full Article

PSG9 Stimulates Increase in FoxP3⁺ Regulatory T-Cells through the TGF-β1 Pathway

Researchers found that pregnancy-specific glycoprotein 9 (PSG9) binds to LAP and activates the latent form of TGF-β1. In addition, PSG9 induces the secretion of TGF-β1 from macrophages but not from CD4⁺ T-cells. [PLoS One] Full Article

Subscribe to our sister publications: Human Immunology News & Immunology of Infectious Disease News.

Emerging Therapies Provide New Opportunities to Reshape the Multifaceted Interactions between the Immune System and Lymphoma Cells

The principles of cancer immunoescape and their role in human lymphomagenesis are illustrated. Current therapies targeting these pathways and possible applications for lymphoma treatment are also addressed. [Leukemia] Abstract

Visit our reviews page to see a complete list of reviews in the immune regulation research field.

OSE Immunotherapeutics Presents New Preclinical Efficacy Results with Effi-DEM, a New Generation Checkpoint Inhibitor

OSE Immunotherapeutics SA announced it presented three posters. The posters included significant efficacy results in preclinical studies conducted in immuno-oncology with Effi-DEM, a new generation checkpoint inhibitor. [Press release from OSE Immunotherapeutics SA discussing research presented at the European Association Cancer Research (EACR) Congress, Manchester] Press Release

CEL-SCI Granted European Patent for Multikine Cancer Immunotherapy in Combination with Radiation and/or Chemotherapy

CEL-SCI Corporation announced that it has been granted a new European patent covering its investigational Phase III cancer immunotherapy drug Multikine. [CEL-SCI Corporation] Press Release

Juno Therapeutics Adds Adenosine Receptor Antagonist through Acquisition of RedoxTherapies

Juno Therapeutics, Inc. announced that it has acquired RedoxTherapies, Inc. The acquisition provides Juno with an exclusive license to vipadenant, a small molecule adenosine A2a receptor antagonist that has the potential to disrupt important immunosuppressive pathways in the tumor microenvironment in certain cancers. [Juno Therapeutics, Inc.] Press Release

Juno Therapeutics to Resume JCAR015 Phase II ROCKET Trial

Juno Therapeutics, Inc. announced that the U.S. Food and Drug Administration has removed the clinical hold on the Phase II clinical trial of JCAR015 in adult patients with relapsed or refractory B cell acute lymphoblastic leukemia. [Juno Therapeutics, Inc.] Press Release

MOLOGEN AG: First Patient Recruited in Combination Study with Lefitolimod and Yervoy^®

MOLOGEN AG announced that its collaborator, the University of Texas MD Anderson Cancer Center, has enrolled the first patient in the combination study with a checkpoint inhibitor. In the Phase I study MOLOGEN’s TLR9 agonist, the Immune Surveillance Reactivator lefitolimod is tested in combination with the immunotherapy ipilimumab in patients with advanced solid malignancies. [MOLOGEN AG] Press Release

Kineta Secures NIAID Funding to Expand Testing of Immune Modulators

Kineta, Inc. announced it has received funding to advance the development of immune modulators. This National Institute of Allergy and Infectious Disease (NIAID) awarded Kineta with a “direct to phase two” SBIR grant of up to $1.5 million over two years. [Kineta, Inc.] Press Release

NEW International Workshop on Waldenstrom’s Macroglobulinemia & Symposium on Multiple Myeloma
October 5-8, 2016
Amsterdam, Netherlands

Visit our events page to see a complete list of events in the immune regulation community.

NEW Postdoctoral Fellow – Cancer Biology and Cancer Immunology (Fox Chase Cancer Center)

NEW Postdoctoral Position – Molecular/Cellular Immunology (National Institute of Allergy and Infectious Diseases)

Technical Sales Representative (STEMCELL Technologies Inc.)

Research Technologist – Cell Separation (STEMCELL Technologies Inc.)

Scientist – Bioengineering (STEMCELL Technologies Inc.)

Senior Scientist – Immunology and Cell Separation (STEMCELL Technologies Inc.)

Senior Faculty Leadership Position – Immunology (Fred Hutchinson Cancer Research Center)

Post Doctoral Research Fellow – T Cell Immunotherapy (Fred Hutchinson Cancer Research Center)

Postdoctoral Position – Immunology (Ludwig-Maximilians-Universität)

Assistant or Associate Professor – Cancer Immunology (University of Virginia)

Postdoctoral Fellow – Immunology (Stanford University)

Research Post Doctoral Fellow – Molecular Immunology/Cell Signaling (Baylor Scott & White Health)

Postdoctoral Scientist – Novel Immune Modulating Drugs (Celenlyx)

Post Doctoral Research – Fellow Thymic and Immune Regeneration (Fred Hutchinson Cancer Research Center)

Recruit Top Talent: Reach potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Have we missed an important article or publication in Immune Regulation News? Click here to submit!

Comments or suggestions? Submit your feedback here.